Department of Gynecology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang 310060, P.R. China.
Department of Clinical Laboratory, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang 310060, P.R. China.
Mol Med Rep. 2022 Jul;26(1). doi: 10.3892/mmr.2022.12761. Epub 2022 Jun 3.
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies and primarily presents with hyperandrogenism. Although environmental factors and genetic factors are thought to be the major reason, there still exists a lot of questions need to be answered. High expression of C‑terminal‑binding protein 1 antisense (CTBP1‑AS) was identified as an independent risk factor for PCOS; however, the molecular mechanism of CTBP1‑AS in PCOS regulation is unknown. In the present study, the expression level of CTBP1‑AS was found to be significantly upregulated in patients with PCOS compared with healthy control patients. CTBP1‑AS knockdown was demonstrated to reduce the proliferation and promote the apoptosis of granulosa tumor cells . It was also identified that the two core catalytic subunits of Polycomb repressive complex 2 (enhancer of zeste homolog 2 and embryonic and ectoderm development protein) interacted with CTBP1‑AS in primary granulosa cells and KGN cells. In addition, cryptotanshinone treatment was demonstrated to effectively downregulate CTBP1‑AS expression level. Data from the present study suggested a pathophysiological role of CTBP1‑AS in PCOS and may provide a new potential target for PCOS treatment.
多囊卵巢综合征（PCOS）是最常见的内分泌疾病之一，主要表现为高雄激素血症。尽管环境因素和遗传因素被认为是主要原因，但仍有许多问题需要解答。C-末端结合蛋白 1 反义（CTBP1-AS）的高表达被确定为 PCOS 的一个独立危险因素；然而，CTBP1-AS 在 PCOS 调节中的分子机制尚不清楚。在本研究中，与健康对照组患者相比，PCOS 患者中 CTBP1-AS 的表达水平显著上调。CTBP1-AS 敲低被证明可减少颗粒细胞瘤的增殖并促进其凋亡。还发现多梳抑制复合物 2 的两个核心催化亚基（EZH2 和胚胎外胚层发育蛋白）与原代颗粒细胞和 KGN 细胞中的 CTBP1-AS 相互作用。此外，隐丹参酮处理被证明可有效下调 CTBP1-AS 的表达水平。本研究的数据表明 CTBP1-AS 在 PCOS 中的病理生理作用，并可为 PCOS 的治疗提供新的潜在靶点。
